医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

DRADS Capital Leads Series C Round for ROKIT Healthcare, a South Korean 4D Bioprinting Company

2020年07月09日 PM09:00
このエントリーをはてなブックマークに追加


 

SEOUL, South Korea

DRADS Capital announced today its investment in ROKIT Healthcare Inc., a South Korean biotechnology company developing innovative 4D bioprinting techniques and applications, in its Series C funding round of undisclosed amount. Founded in 2018, DRADS Capital is a Boston-based venture capital fund which specializes in making strategic investments in life sciences, biotechnology and artificial intelligence (AI). One of its notable founders is Dr. Rudolph E. Tanzi, who is the Joseph P. and Rose F. Kennedy Professor of Neurology at Harvard University, Vice-Chair of Neurology and Director of the Genetics and Aging Research Unit at Massachusetts General Hospital (MGH). He was also named to TIME magazine’s list of TIME 100 Most Influential People in the World in 2015.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200709005332/en/

DRADS Capital announced its investment in ROKIT Healthcare Inc., a South Korean biotechnology company developing innovative 4D bioprinting techniques and applications, in its Series C funding round of undisclosed amount. DRADS Capital is a Boston-based venture capital fund which specializes in making strategic investments in life sciences, biotechnology and artificial intelligence. ROKIT Healthcare Inc. introduces a cutting-edge organ regeneration platform based on 4D printing and clinical diagnosis technology for age-related diseases, such as rheumatoid arthritis and Alzheimer’s disease, to the global anti-aging market. (Graphic: Business Wire)

DRADS Capital announced its investment in ROKIT Healthcare Inc., a South Korean biotechnology company developing innovative 4D bioprinting techniques and applications, in its Series C funding round of undisclosed amount. DRADS Capital is a Boston-based venture capital fund which specializes in making strategic investments in life sciences, biotechnology and artificial intelligence. ROKIT Healthcare Inc. introduces a cutting-edge organ regeneration platform based on 4D printing and clinical diagnosis technology for age-related diseases, such as rheumatoid arthritis and Alzheimer’s disease, to the global anti-aging market. (Graphic: Business Wire)

Nagarajan Pillay, founding Managing Director of DRADS Capital and former Senior Vice President of Pepsi Bottling Franchise, commented on the investment, “We stand behind ROKIT’s fundamental belief that ‘aging is disease’ and their aim to change the world with customized organ regeneration platforms. As the lead investor in ROKIT’s Series C funding round, we believe that ROKIT’s novel organ regeneration technology will dramatically improve clinical therapeutics in the field of wound healing. Their recently published paper in the Diabetes Journal shows how their 4D bioprinter ‘Dr. INVIVO’ — the world’s first sterile, all-in-one 4D organ regenerator — is used to regenerate skin as a treatment for diabetic foot ulcers, negating the need for amputation and skin grafting. It is without a doubt that ROKIT Healthcare Inc. will make great strides under the leadership of Chairman Seokhwan You in the era of organ regeneration.” Dr. Tanzi also expressed his excitement about ROKIT, stating “We are thrilled and honored to be aligned with ROKIT Healthcare and the tremendous promise of their regenerative bioprinting technologies.”

Chairman You, the founder and CEO of ROKIT Healthcare Inc., stated: “ROKIT introduces a cutting-edge organ regeneration platform based on 4D printing and clinical diagnosis technology for age-related diseases, such as rheumatoid arthritis and Alzheimer’s disease, to the global anti-aging market.” Chairman You, who is also the former CEO of Celltrion Healthcare, a South Korean biopharmaceutical company valued at $14 billion today, added: “With our extensive experiences in the biomedical industry, ROKIT Healthcare will make every effort to continue growing as an innovative global company by expanding its business domain ranging from personalized organ regeneration to anti-aging markets. This will be headed by our revolutionary Diabetic Foot Ulcer Platform, DFURegen, which will combat this incurable disease with a global market share of about USD 40 billion.” The company plans to go public in 2021.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200709005332/en/

CONTACT

ROKIT Healthcare Inc.

Sujin Kim, CHRO & CMO

+82-2-867-0182

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • Seoul Viosys’ Violeds Modules Proven to Disinfect 99% of Airborne Viruses in a Recent Testing Result
  • Aurinia Announces Collaboration and Licensing Agreement with Otsuka Pharmaceutical Co., Ltd. for the Development and Commercialization of Voclosporin in Europe and Japan
  • Kaye推出适用于冷链运输市场的Kaye® Log -80℃ 疫苗温度记录器,以满足COVID-19疫苗储存和运输的要求
  • Kaye® (ケイ)は、COVID-19ワクチンの輸送・保管のニーズに応えるためにKaye® ログ -80ワクチン温度ロガーを、コールドチェーン市場向けに導入(発売)します。
  • DNP的新型非接触式透明屏幕可通过手的动作进行操作